Evaluating Morphine Effectiveness Based on Kidney Function in Patients with Sickle Cell Disease During Vaso-occlusive Crisis

3 1 1 1

What is this study about?

This clinical study aims to improve pain management for individuals with sickle cell disease who are experiencing vaso-occlusive crisis and/or acute chest syndrome while in intensive care. Sickle cell disease is an inherited blood disorder where red blood cells become crescent-shaped and can block blood vessels, causing severe pain episodes. The study focuses on how the kidneys process morphine, which is commonly used to treat severe pain in these patients.

The research evaluates how well the kidneys filter blood (called glomerular filtration) and how this affects morphine processing in the body. By measuring kidney function using iohexol clearance (a reference method) and comparing it to a kidney function estimation tool (CKD-Epi score), researchers hope to determine when standard morphine doses might not provide adequate pain relief for certain patients.

Understanding the relationship between kidney function and morphine effectiveness could help doctors identify which patients need higher initial doses of pain medication. This would allow for more personalized pain management strategies for people with sickle cell disease during painful crises, potentially improving treatment outcomes and patient comfort.

1 Admission to the study

You will be admitted to a Continuous Care Unit (CCU) or intensive care unit with a vaso-occlusive crisis (severe pain episodes) or acute chest syndrome related to your sickle cell disease.

Upon admission, your kidney function will be assessed using a standard blood test that calculates your glomerular filtration rate (GFR) using the CKD-Epi formula, which measures how well your kidneys are filtering blood.

2 Pain management setup

You will receive a patient-controlled analgesia (PCA) device containing morphine hydrochloride (1 mg/ml solution). This device allows you to self-administer small doses of morphine when needed for pain relief.

The healthcare team will record your pain levels using numerical scales where you rate your pain from 0-10. This will help track how effectively your pain is being managed.

3 Kidney function assessment

You will receive an injection of iohexol (300 mg I/ml), a substance that helps measure kidney function more precisely.

Blood samples will be collected at specific intervals to measure how quickly your kidneys clear the iohexol. This is considered a reference method for assessing kidney function.

4 Morphine clearance monitoring

Blood samples will be collected to measure how your body processes morphine and its metabolites (M3G and M6G).

The healthcare team will monitor and record the total amount of morphine you receive over 24 hours and throughout the 7-day study period.

5 Pain assessment

Your pain levels will be regularly evaluated using numerical scales over the 24-hour period.

At the 24-hour mark, you will complete a Patient Global Impression of Change (PGIC) scale to indicate how much your condition has improved or worsened.

6 Side effect monitoring

Throughout the study, you will be monitored for possible side effects of morphine including drowsiness, slow breathing, high carbon dioxide levels, itching, constipation, bloating, nausea, vomiting, and difficulty urinating.

All these observations are part of standard care for patients receiving morphine.

7 Study completion

The study data collection will conclude after 7 days or upon your discharge from the hospital, whichever comes first.

The results will help determine if kidney function affects how well morphine works for pain relief in sickle cell patients, which may lead to more personalized pain management in the future.

Who Can Join the Study?

You must be 18 years or older
You must have a known homozygous sickle cell disease (types SS, SC, S-beta+ or S-beta0)
You must be admitted to a Continuous Care Unit (CCU) or intensive care unit
You must have a clinical diagnosis of vaso-occlusive crisis (painful episode caused by blocked blood vessels) and/or acute chest syndrome (a serious lung complication of sickle cell disease)
You must be receiving morphine PCA therapy (patient-controlled analgesia where you can self-administer pain medication)
You must have given consent to participate in the study (or a parent/relative has given consent if you are unable to)
You must be affiliated with a social security scheme

Who Cannot Join the Study?

If you are under 18 years old or over 75 years old
If you are a woman who is pregnant or breastfeeding
If you are unable to give your consent to participate in the study
If you have a kidney disease (problem with how your kidneys work)
If you have a previous history of allergic reaction to morphine or other similar pain medications
If you have a previous history of allergic reaction to iohexol (a substance used to measure kidney function in this study)
If you are currently taking part in another clinical trial
If you do not have health insurance coverage
If you have been placed under legal protection (such as guardianship)

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country
Centre Hospitalier Universitaire d’Orléans	Orléans	France
Centre Hospitalier Le Mans	Le Mans	France
Centre Hospitalier Universitaire De Nantes	Nantes	France
Centre Hospitalier Universitaire De Rennes	Rennes	France
Hopital Beaujon	Clichy	France
Csfjlo Hixxqbmjere Raahiblf Ufxaiorajbslh Dh Tnylw	Tours	France

Trial status

Country	Status	Recruitment Start
France	Recruiting	01.07.2025

Trial locations

Investigated drugs:

Morphine is a medication used for pain relief. In this study, it is being used to treat severe pain experienced during vaso-occlusive crises in patients with sickle cell disease. The researchers are studying how the kidney’s ability to filter blood (glomerular filtration) affects how quickly morphine is cleared from the body, which may impact its effectiveness for pain control.

Investigated diseases:

Sickle cell anaemia

Sickle Cell Disease – Sickle cell disease is an inherited blood disorder characterized by abnormal hemoglobin that causes red blood cells to become rigid and C-shaped (sickle-shaped). These abnormal cells can block blood vessels, reducing blood flow and oxygen to body tissues. The disease is marked by episodes of intense pain called vaso-occlusive crises that occur when sickle cells block small blood vessels. Over time, sickle cell disease can affect multiple organs including the lungs, kidneys, spleen, and bones. The condition typically manifests in early childhood and varies in severity among affected individuals.

Chronic Kidney Disease – Chronic kidney disease is a condition characterized by gradual loss of kidney function over time. The kidneys filter wastes and excess fluids from the blood, which are then excreted in urine. As kidney function declines, waste products accumulate in the blood. The disease progresses through five stages of increasing severity based on glomerular filtration rate (GFR). CKD may initially present with few symptoms but can eventually lead to complications like high blood pressure, anemia, bone disease, and fluid buildup. The condition develops slowly over months or years and may result from various underlying causes.

Trial ID:

2024-511985-34-00

Protocol code:

DR230314

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Evaluating Morphine Effectiveness Based on Kidney Function in Patients with Sickle Cell Disease During Vaso-occlusive Crisis

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?